CRUK International Symposium on Oesophageal Cancer 2017
Our second International Symposium on Oesophageal Cancer is a unique opportunity to unite basic biologists, translational scientists and clinicians working on both adenocarcinoma and squamous cell carcinoma. But it’s also a chance for those not currently in the field to learn more about this fascinating disease.
It’s never been a better time to enter the field. Insights from sequencing data and the development of new model systems are bringing oesophageal cancer research out of the shadows, revealing a biologically complex and intriguing malady. Whether you’re an early-career researcher or an established PI, this is an arena rife with opportunity and the potential for your research to have real impact.
The symposium will bring together world experts across a range of disciplines to discuss the latest advances and to debate the current challenges in oesophageal cancer research. We are keen to create a workshop atmosphere, providing plenty of opportunity for networking and sharing of expertise across disciplines. On behalf of the Scientific Committee and Cancer Research UK we look forward to seeing you in Cambridge.
Prof Rebecca Fitzgerald, Scientific Committee
Oesophageal cancer is a real challenge but the field is moving faster than ever before. It’s such an exciting time to be an oesophageal cancer researcher so I urge everyone, particularly those not currently in the field, to come to Cambridge and see just how many opportunities there are.
Prof Xin Lu, Scientific Committee
There’s so much we don’t know about oesophageal cancer, the field has something to offer everyone – regardless of research speciality or career stage. Our scientific programme reflects the broad spectrum of expertise we need to make progress for patients and I’m looking forward to what will be a thought-provoking and exciting event.
Prof Laurence Lovat, Scientific Committee
Research opportunities in oesophageal cancer
Survival rates for oesophageal cancer have barely moved in decades, which is why we’ve made it a strategic priority. We have a broad range of funding opportunities for researchers wanting to focus on the disease.